Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia

Abstract

(1) Background: The assessment of vaccine effectiveness against the Omicron variant is vital in the fight against COVID-19, but research on booster vaccine efficacy using nationwide data was lacking at the time of writing. This study investigates the effectiveness of booster doses on the Omicron wave in Malaysia against COVID-19 infections and deaths; (2) Methods: This study uses nationally representative data on COVID-19 from 1 January to 31 March 2022, when the Omicron variant was predominant in Malaysia. Daily new infections, deaths, ICU utilization and Rt values were compared. A screening method was used to predict the vaccine effectiveness against COVID-19 infections, whereas logistic regression was used to estimate vaccine effectiveness against COVID-19-related deaths, with efficacy comparison between AZD1222, BNT162b2 and CoronaVac; (3) Results: Malaysia’s Omicron wave started at the end of January 2022, peaking on 5 March 2022. At the time of writing, statistics for daily new deaths, ICU utilization, and effective reproductive values (Rt) were showing a downtrend. Boosted vaccination is 95.4% (95% CI: 95.4, 95.4) effective in curbing COVID-19 infection, compared to non-boosted vaccination, which is 87.2% (95% CI: 87.2, 87.2). For symptomatic infection, boosted vaccination is 97.4% (95% CI: 97.4, 97.4) effective, and a non-boosted vaccination is 90.9% (95% CI: 90.9, 90.9). Against COVID-19-related death, boosted vaccination yields a vaccine effectiveness (VE) of 91.7 (95% CI: 90.6, 92.7) and full vaccination yields a VE of 65.7% (95% CI: 61.9, 69.1). Looking into the different vaccines as boosters, AZD1222 is 95.2% (CI 95%: 92.7, 96.8) effective, BNT162b2 is 91.8% (CI 95%: 90.7, 92.8) effective and CoronaVac is 88.8% (CI 95%: 84.9, 91.7) effective against COVID-19 deaths. (4) Conclusions: Boosters are effective in increasing protection against COVID-19, including the Omicron variant. Given that the VE observed was lower, CoronaVac recipients are encouraged to take boosters due to its lower VE.

Analysis of the impact of COVID-19 variants and vaccination on the time-varying reproduction number: statistical methods

“…Due to a significant number of infections and primary and booster vaccination drives in Malaysia, herd immunity has been achieved within the population. Consequently, the value of in Malaysia is considerably lower than that in other countries ( 22 ). However, this condition does not mean that herd immunity will continue indefinitely.…”

Comparison of Antibody Persistence Up to 6 Months After Additional Booster Vaccination With ChAdOx1 nCoV-19 Vaccine.

“…Although neutralization activity against the Omicron subtypes BA.1 and BA.2 was lower, it was still sufficient to protect against severe disease caused by these variants. This was demonstrated in a vaccine efficacy study where participants received two doses of CoronaVac followed by a third dose booster of ChAdOx1 nCoV-19 [16].…”

An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations

“…The effectiveness of AZD1222, BNT162b2, and CoronaVac booster doses on the mortality rate was 95.2%, 91.8%, and 88.8%, respectively. According to the obtained results, booster doses had been more effective against the sysmtoms caused by infection than non-boosted vaccination [118] .…”